N-(m-tolyl)-1H-benzo[d]imidazol-2-amine | 83318-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-(m-tolyl)-1H-benzo[d]imidazol-2-amine
• 英文别名: N-(3-methylphenyl)-1H-benzimidazol-2-amine
• CAS: 83318-14-3
• 化学式: C₁₄H₁₃N₃
• 分子量: 223.277
• InChiKey: NMORHVKBDAKIFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(m-tolyl)-1H-benzo[d]imidazol-2-amine 以 苯 为溶剂， 生成 1-(1H-Benzoimidazol-2-yl)-3-phenyl-1-m-tolyl-urea
  参考文献：
  名称：

  Graubaum, Heinz; Martin, Dieter; Gruendemann, Egon, Zeitschrift fur Chemie, 1982, vol. 22, # 8, p. 308 - 309

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴苯胺 在 1,10-菲罗啉 、 copper(ll) sulfate pentahydrate 、 sodium acetate 、 potassium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 N-(m-tolyl)-1H-benzo[d]imidazol-2-amine
  参考文献：
  名称：

  铜促进的一锅法：苯并咪唑的合成

  摘要：

  开发了一种简便、一锅式且熟练的方法来生产各种 2-芳基氨基苯并咪唑。该方法首次基于铜催化剂促进多米诺 C-N 交叉偶联反应生成 2-芳基氨基苯并咪唑。机理研究表明，合成途径涉及基于铜的脱硫/亲核取代和随后的多米诺骨牌内和分子间 C-N 交叉偶联反应。使用这种新开发的铜催化方法解决了 2-芳基氨基苯并咪唑合成过程中通常遇到的一些问题，包括使用昂贵的催化系统和溴前体的低反应性。反应过程简单，一般具有优良的底物耐受性，

  DOI：

  10.3390/molecules25081788

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2017015451A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式（I），或其药用可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物能够抑制由乙型肝炎病毒（HBV）编码的蛋白质，或干扰乙型肝炎病毒的生命周期功能，同时也可作为抗病毒药物使用。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170022150A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A 1 -Y-A 2 -Z-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的化学式（I），或其药学上可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于给患有HBV感染的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Novel Synthesis of 2-Aminobenzimidazoles from Isoselenocyanates
  作者：Yuanyuan Xie、Fan Zhang、Jianjun Li、Xiangjun Shi

  DOI：10.1055/s-0029-1219395

  日期：2010.4

  An efficient one-pot procedure for the synthesis of 2-aminobenzimidazoles from isoselenocyanates and various substituted diamines is described. Precipitation of elemental selenium from the reaction mixture greatly simplifies the purification procedure and also allows it to be re-used for preparation of isoseleno­cyanates. A possible mechanism for the formation of 2-aminobenzimidazoles is proposed.

  描述了一种高效的一锅法合成2-氨基苯并咪唑的程序，该反应使用了异硒氰酸酯和各种取代二胺。从反应混合物中沉淀出的元素硒大大简化了纯化程序，并且还允许其被重新用于制备异硒氰酸酯。提出了一种可能的2-氨基苯并咪唑形成机制。
• Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-<i>a</i>]benzimidazol-5(6<i>H</i>)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity
  作者：Matthew W. Martin、John Newcomb、Joseph J. Nunes、Christina Boucher、Lilly Chai、Linda F. Epstein、Theodore Faust、Sylvia Flores、Paul Gallant、Anu Gore、Yan Gu、Faye Hsieh、Xin Huang、Joseph L. Kim、Scot Middleton、Kurt Morgenstern、Antonio Oliveira-dos-Santos、Vinod F. Patel、David Powers、Paul Rose、Yanyan Tudor、Susan M. Turci、Andrew A. Welcher、Debra Zack、Huilin Zhao、Li Zhu、Xiaotian Zhu、Chiara Ghiron、Monika Ermann、David Johnston、Carl-Gustaf Pierre Saluste

  DOI：10.1021/jm701095m

  日期：2008.3.1

  Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological, characterization of 2-amino-6phenylpyrirnido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5',4':5,6]pyrimido-[1,2-a]benzimidazol-5(6H)-one (25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.
• Synthesis of 2-Aryliminoimidazolidines and 2-Arylaminobenzimidazoles from Methyl<i>N</i>-Aryldithiocarbamates
  作者：F. Merchán、J. Garín、V. Martínez、E. Meléndez

  DOI：10.1055/s-1982-29846

  日期：——